CXXC5 and acute myeloid leukemia: The de-regulated expression of CXXC5 is also suggested to correlate with the development, and resistance to therapies, of various pathologies including cardiovascular disease, diminished ovarian reserve (DOR), Blepharophimosis Ptosis Epicantus inversus Syndrome (BPES), Acute Myeloid Leukemia (AML) and breast cancer12, 18, 19, 20, 21, 22, 23.